Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Recs

1
Player Avatar madman27 (< 20) Submitted: 6/11/2012 9:22:38 PM : Outperform Start Price: $7.27 ARNA Score: -95.19

Lorcaserin is far safer than Qnexa (see new FoxNews video on Qnexa's poor safety) and given the fact that Qnexa's review has been delayed by three months, it seems that Lorcaserin will be first to market. With manufacturing facilities ready to go (in Switzerland) and a strong partner already signed up, we seem to be geared up to witness a blockbuster stock.

Featured Broker Partners


Advertisement